Hawaii Biotech to Begin West Nile Vaccine Clinical Trials
Hawaii Biotech, Inc., (Honolulu, HI), has been notified by the United States Food and Drug Administration (FDA) that it may initiate a 24 patient safety study in healthy human volunteers with its recombinant, subunit West Nile vaccine.
Hawaii Biotech, Inc. (Honolulu, HI), has been notified by the United States Food and Drug Administration (FDA) that it may initiate a 24 patient safety study in healthy human volunteers with its recombinant, subunit West Nile vaccine. The trial will be conducted at a single site in Hawaii, which the company currently expects to start in April 2008. Depending on the actual start date, results of the trial may be available by the end of 2008.
There is currently no vaccine for the prevention of West Nile disease in humans, a disease that has caused over 25,000 cases of disease and over 1,000 deaths since it was introduced in the US in 1999.
Hawaii Biotech web site
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
